TABLE 4.
sCD4 and neutralizing gp41-directed MAbs inhibit infectivity synergistically in an HBX2 Env-pseudotyped virus neutralization assaya
| Ab | Ab/sCD4 Combination ratio | DRI (mean ± SD)
|
CI (mean ± SD) | |
|---|---|---|---|---|
| Ab | sCD4 | |||
| bF-3674 | 10:1 | 2.5 ± 0.7 | 11.8 ± 3.7 | 0.5 ± 0.3 |
| 20:1 | 3.1 ± 1.0 | 30.2 ± 8.6 | 0.4 ± 0.2 | |
| 40:1 | 1.7 ± 0.5 | 45.3 ± 10.6 | 0.6 ± 0.3 | |
| 2F5 | 1:5 | 9.6 ± 2.7 | 11.0 ± 3.3 | 0.2 ± 0.1 |
| 1:10 | 22.4 ± 8.7 | 12.9 ± 5.0 | 0.13 ± 0.08 | |
| 4E10 | 1:5 | 9.7 ± 2.6 | 5.9 ± 1.9 | 0.3 ± 0.1 |
| 1:10 | 17.5 ± 3.2 | 5.2 ± 1.3 | 0.3 ± 0.1 | |
a
The IC50s of the antibodies alone are as follows: bF-3674, 88 ± 14 nM; 2F5, 3.8 ± 1.0 nM; 4E10, 6.3 ± 3.7 nM. The IC50 for sCD4 is 27.2 ± 4.9 nM.